181 related articles for article (PubMed ID: 35149566)
1. Investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson's disease with chronic constipation: a multicentre, placebo-controlled, randomised, double-blind, parallel-group stud (CONST-PD).
Hatano T; Oyama G; Shimo Y; Ogaki K; Nishikawa N; Fukae J; Nakamura R; Kurita N; Tsunemi T; Oji Y; Saiki S; Nishioka K; Takeshige-Amano H; Taniguchi D; Ogawa T; Kamo H; Eguchi H; Fuse A; Nakajima A; Kano M; Nakajima S; Yanagisawa N; Hattori N
BMJ Open; 2022 Feb; 12(2):e054129. PubMed ID: 35149566
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Elobixibat in Parkinson's Disease with Chronic Constipation: CONST-PD Study.
Hatano T; Oyama G; Shimo Y; Ogaki K; Nishikawa N; Nakamura R; Tsunemi T; Ogawa T; Eguchi H; Daida K; Kurita N; Ueno SI; Fukae J; Sako W; Shiina K; Nakajima S; Oji Y; Wakamori R; Saiki S; Nishioka K; Okuzumi A; Taniguchi D; Takeshige-Amano H; Fuse A; Nakajima A; Kano M; Kamo H; Yamashita Y; Shindo A; Yanagisawa N; Hattori N
Mov Disord Clin Pract; 2024 Apr; 11(4):352-362. PubMed ID: 38264844
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
4. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
Nakajima A; Seki M; Taniguchi S
J Gastroenterol; 2018 Apr; 53(4):525-534. PubMed ID: 28840422
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation.
Tanaka K; Kessoku T; Yamamoto A; Takahashi K; Kasai Y; Ozaki A; Iwaki M; Kobayashi T; Yoshihara T; Misawa N; Kato T; Arimoto J; Fuyuki A; Sakai E; Higurashi T; Chiba H; Hosono K; Yoneda M; Iwasaki T; Kurihashi T; Nakatogawa M; Suzuki A; Taguri M; Oyamada S; Ariyoshi K; Kobayashi N; Ichikawa Y; Nakajima A
BMJ Open; 2022 May; 12(5):e060704. PubMed ID: 35636802
[TBL] [Abstract][Full Text] [Related]
6. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial.
Kumagai Y; Amano H; Sasaki Y; Nakagawa C; Maeda M; Oikawa I; Furuie H
Br J Clin Pharmacol; 2018 Oct; 84(10):2393-2404. PubMed ID: 29959787
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan.
Nakajima A; Taniguchi S; Kurosu S; Gillberg PG; Mattsson JP; Camilleri M
Neurogastroenterol Motil; 2019 May; 31(5):e13571. PubMed ID: 30793431
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological characteristics and clinical study results of ileal bile acid transporter inhibitor elobixibat (GOOFICE
Ikeda N; Taniguchi S; Seki M
Nihon Yakurigaku Zasshi; 2019; 153(3):129-138. PubMed ID: 30867382
[TBL] [Abstract][Full Text] [Related]
9. Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake.
Ozaki A; Kessoku T; Kasai Y; Takeda Y; Okubo N; Iwaki M; Kobayashi T; Yoshihara T; Honda Y; Fuyuki A; Higurashi T; Ishiki H; Taguri M; Oyamada S; Kobayashi N; Nakajima A; Ichikawa Y
Oncologist; 2021 Oct; 26(10):e1862-e1869. PubMed ID: 34180099
[TBL] [Abstract][Full Text] [Related]
10. Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study.
Kamei D; Kamei Y; Nagano M; Mineshima M; Nitta K; Tsuchiya K
BMC Gastroenterol; 2020 Jan; 20(1):26. PubMed ID: 32005162
[TBL] [Abstract][Full Text] [Related]
11. Elobixibat for the treatment of constipation.
Chedid V; Vijayvargiya P; Camilleri M
Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):951-960. PubMed ID: 30204504
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of electroacupuncture for the treatment of constipation in Parkinson's disease: study protocol for a multicentre randomised controlled trial.
Li K; Wang Z; Chen Y; Shen L; Li Z; Wu Y; Yuan C; Huang Y; Wu L; Bao C; Zhang W; Xu S; Wu H
BMJ Open; 2019 Nov; 9(11):e029841. PubMed ID: 31780587
[TBL] [Abstract][Full Text] [Related]
13. Effects of Elobixibat in Patients with Diabetes and Concomitant Chronic Constipation: an 8-week, Prospective, Single-center, Single-arm Study.
Hishida Y; Nagai Y; Tsukiyama H; Nakamura Y; Nakagawa T; Ishizaki S; Tanaka Y; Sone M
Adv Ther; 2022 Sep; 39(9):4205-4217. PubMed ID: 35867276
[TBL] [Abstract][Full Text] [Related]
14. A randomized double-blind placebo-controlled multicenter trial of Bushen Yisui and Ziyin Jiangzhuo formula for constipation in Parkinson disease.
Jin Z; Liu Z; Kang L; Yang A; Zhao H; Yan X; Zhang T; Gao L; Liu A; Fang B
Medicine (Baltimore); 2020 Jul; 99(28):e21145. PubMed ID: 32664145
[TBL] [Abstract][Full Text] [Related]
15. Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation.
Miner PB
Expert Opin Pharmacother; 2018 Aug; 19(12):1381-1388. PubMed ID: 30129377
[TBL] [Abstract][Full Text] [Related]
16. Review article: Elobixibat: a novel treatment for chronic constipation.
Khanna L; Camilleri M
Aliment Pharmacol Ther; 2021 Jan; 53(2):234-242. PubMed ID: 33296518
[TBL] [Abstract][Full Text] [Related]
17. Elobixibat improves rectal sensation in patients with chronic constipation aged ≥60 years: a randomised placebo-controlled study.
Manabe N; Umeyama M; Ishizaki S; Ota T; Kuratani S; Katsumata R; Fujita M; Haruma K; Camilleri M
BMJ Open Gastroenterol; 2023 Nov; 10(1):. PubMed ID: 37993269
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease.
Kessoku T; Kobayashi T; Ozaki A; Iwaki M; Honda Y; Ogawa Y; Imajo K; Saigusa Y; Yamamoto K; Yamanaka T; Usuda H; Wada K; Yoneda M; Saito S; Nakajima A
BMJ Open; 2020 Sep; 10(9):e037961. PubMed ID: 32907904
[TBL] [Abstract][Full Text] [Related]
19. Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation.
Nakajima A; Ishizaki S; Matsuda K; Kurosu S; Taniguchi S; Gillberg PG; Mattsson JP; Hasunuma T; Camilleri M
J Gastroenterol Hepatol; 2022 May; 37(5):883-890. PubMed ID: 35168298
[TBL] [Abstract][Full Text] [Related]
20. Effects of Elobixibat, an Inhibitor of Ileal Bile Acid Transporter, on Glucose and Lipid Metabolism: A Single-arm Pilot Study in Patients with T2DM.
Yoshinobu S; Hasuzawa N; Nagayama A; Iwata S; Yasuda J; Tokubuchi R; Kabashima M; Gobaru M; Hara K; Murotani K; Moriyama Y; Ashida K; Nomura M
Clin Ther; 2022 Oct; 44(10):1418-1426. PubMed ID: 36117045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
